Supporting new Alzheimer’s Disease research
One of our US investments – Evidation – partners with Merck on new dementia study
September 10, 2021
Reading time: 1 minute
September is World Alzheimer’s Month, so we wanted to use this week’s post to share some news about what one of our investments is up to.
Evidation – a US investment since earlier this year – announced over the summer an exciting new partnership to investigate the usefulness of remotely collecting digital data to detect and monitor the treatment of Alzheimer’s Disease.
In collaboration with Merck (known as MSD outside the United States and Canada), the study hopes to determine if sensor data can be used to develop digital measures to accelerate drug development to treat the disease.
The companies will conduct an initial study by collecting data from smartphones and wearable devices. The study will test whether the data can be used to differentiate between people, and to understand any variances and changes in digital measures across people and over time.